ARUP's Laboratory Test Directory

Multiple Endocrine Neoplasia Type 2B (MEN2B), RET Gene M918T & A883F Mutations : 0051492
[ image for: Patient History for Multiple Endocrine Neoplasia]
Patient History for Multiple Endocrine Neoplasia
  


Mnemonic: MEN 2 B

Methodology: Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Mon, Thu
Reported: 7-10 days
Specimen Required: Collect:  One 3 mL lavender (EDTA) or pink (K2EDTA).

Transport:  3 mL whole blood at 2-8°C. (Min: 1 mL)

Pediatric Collection/Transport:  1 mL whole blood at 2-8°C.

Stability:  Ambient: 3 days; Refrigerated: 1 week; Frozen: Unacceptable
Reference Interval:
By report
Interpretive Data: Background Information:
Characteristics:
Medullary carcinoma of the thyroid, pheochromocytoma, mucosal neuromas, and Marfanoid body habitus.
Incidence:
Approximately 1:600,000
Inheritance:
Autosomal dominant; 50% of cases caused by de novo mutations.
Penetrance:
100% for medullary thyroid carcinoma, 50% for pheochromocytoma.
Cause
: RET proto-oncogene mutations.
Mutations Tested:
M918T, A883F
Clinical Sensitivity:
98%
Methodology:
Polymerase chain reaction followed by unlabeled probe and melting curve analysis.
Analytical Sensitivity and Specificity:
99%
Limitations:
RET mutations, other than M918T and A883F, will not be identified.





Please refer to Statement C in the Compliance Statements section in the front of the Laboratory Test Directory.
CPT Code(s): 83890 Isolation; 83898 x2 Amplification; 83896 x2 Nucleic acid probes; 83912 Interpretation and report. Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org